Wednesday, 20 March 2019

Novo Nordisk submits diabetes pill for U.S. approval

Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)